Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma

Mark R. Gilbert, Jeffrey G. Supko, Tracy Batchelor, Glenn Lesser, Joy D. Fisher, Steven Piantadosi, Stuart Grossman

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: A preliminary evaluation of the efficacy of irinotecan in patients with malignant glioma demonstrated modest activity. A markedly lower than expected incidence of drug-related toxicity was also noted. This was consistent with pharmacokinetic data indicating that the total body clearance (CL) of irinotecan in this patient population was considerably greater than in colorectal cancer patients. Concomitant medications used chronically in brain cancer patients, especially glucocorticoids and anticonvulsants that induce hepatic enzymes involved in the metabolism or excretion of drugs, were believed to be the cause of the alteration in pharmacokinetic behavior. A Phase I study was therefore undertaken in patients with recurrent malignant gliomas to independently determine the maximum tolerated dose (MTD) of irinotecan in patients stratified according to the use of enzyme-inducing anticonvulsants (EIAs). Experimental Design: Patients with recurrent malignant gliomas received irinotecan as a weekly 90-min i.v. infusion for four consecutive weeks, with additional cycles of treatment repeated every 6 weeks. The starting dose was 125 mg/m2/week for both groups of patients (+/-EIA). Groups of ≥3 patients were evaluated at each dose level, and the modified continual reassessment method was used for dose adjustments. The plasma pharmacokinetics of irinotecan, its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), and the glucuronide conjugate of SN-38, SN-38 glucuronide, were determined in all patients during treatment with the first weekly dose. Results: Forty patients were enrolled into the study and treated with a total of 135 cycles of irinotecan. The MTD was determined to be 411 mg/m2/week in the +EIA cohort and 117 mg/m2/week in the -EIA cohort for the weekly × 4 every 6 weeks schedule. Pharmacokinetic studies showed that the CL of irinotecan was distinctly dose dependent in the patients receiving EIAs, decreasing from ∼50 liters/h/m2 at the lower dose levels (125-238 mg/m2) to a mean ± SD value of 29.7 ± 9.0 liters/h/m2 (n = 7) at the MTD. The grand mean CL for a group of 13 patients who were not taking EIAs, 18.8 ± 10.6 liters/h/m2 was significantly different from the mean CL at the MTD of the +EIA cohort (P = 0.033). Mean values of the AUC of SN-38 (P = 0.4) and SN-38 glucuronide (P = 0.55) were not significantly different at the MTDs for the two cohorts of patients. Conclusions: The MTD of irinotecan was 3.5 times greater in patients with malignant glioma, who were cocurrently receiving EIAs than in those who were not. This study has also served to confirm that the concomitant administration of EIAs results in marked enhancement in the CL of irinotecan. These findings have important implications for subsequent clinical trials to further evaluate irinotecan in brain cancer patients and underscore the importance of assessing the potential for pharmacokinetic interactions between concurrent medications and chemotherapeutic agents.

Original languageEnglish (US)
Pages (from-to)2940-2949
Number of pages10
JournalClinical Cancer Research
Volume9
Issue number8
StatePublished - Aug 1 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma'. Together they form a unique fingerprint.

Cite this